Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma

Nam H. Dang*, Luis Fayad, Peter McLaughlin, Jorge E. Romaguara, Fredrick Hagemeister, Andre Goy, Sattva Neelapu, Felipe Samaniego, Pamela L. Walker, Michael Wang, Maria A. Rodriguez, Ann T. Tong, Barbara Pro

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Abstract

Denileukin diftitox plus rituximab was evaluated in relapsed/refractory B-cell non-Hodgkin lymphoma patients. Of the 38 evaluable patients, 30 (80%) were rituximab-refractory. The overall response rate (ORR) was 32%, with six complete responses (CR) and six partial responses (PR). The median time to progression for responders was 8 months (range: 2-36+); two patients with rituximab-refractory follicular lymphoma were in CR at 25 and 36+ months. The ORR was 55% (4 CRs, 2 PRs) in 11/14 patients with rituximab-refractory follicular lymphoma, and 100% in the three patients with rituximab-sensitive tumour. Most toxicities were low grade and transient, and myelotoxicity was uncommon.

Original languageEnglish (US)
Pages (from-to)502-505
Number of pages4
JournalBritish Journal of Haematology
Volume138
Issue number4
DOIs
StatePublished - Aug 2007

Keywords

  • Denileukin difitox
  • Follicular lymphoma
  • Non-Hodgkin lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this